 Ezetimibe, a cholesterol-absorption inhibitor, significantly lowers low-density lipoprotein cholesterol LDL-C when administered in addition to statin treatment. The effect of ezetimibe on the incidence and progression of vascular disease is elusive. Therefore, our objective was to examine the effects of fluvastatin and fluvastatin plus ezetimibe on lipoprotein subfractions in patients with diabetes mellitus andor coronary heart disease. 